Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRTXNASDAQ:DMTKNASDAQ:MGRXNYSE:SSY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXBiorestorative Therapies$1.58-0.4%$1.72$1.21▼$2.55$11.93M75.28142,735 shs43,517 shsDMTKDermTech$0.19$0.09▼$3.90$3.29M2.481.07 million shs3.66 million shsMGRXMangoceuticals$1.55+1.6%$1.82$1.32▼$7.66$7.86M2.4219,285 shs72,419 shsSSYSunLink Health Systems$0.89-2.1%$0.91$0.62▼$1.91$6.24M1.11115,130 shs63,618 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXBiorestorative Therapies-0.38%-5.15%-11.01%-8.17%-15.29%DMTKDermTech0.00%0.00%0.00%0.00%-26.67%MGRXMangoceuticals+1.64%-14.17%-26.43%-16.03%-97.76%SSYSunLink Health Systems-4.01%+1.93%+1.96%+1.08%+16.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRTXBiorestorative Therapies2.7865 of 5 stars3.53.00.00.00.63.30.6DMTKDermTechN/AN/AN/AN/AN/AN/AN/AN/AMGRXMangoceuticals0.8748 of 5 stars0.05.00.00.00.01.70.6SSYSunLink Health SystemsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXBiorestorative Therapies 3.00Buy$18.001,036.36% UpsideDMTKDermTech 0.00N/AN/AN/AMGRXMangoceuticals 0.00N/AN/AN/ASSYSunLink Health Systems 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXBiorestorative Therapies$400K29.70N/AN/A$1.23 per share1.29DMTKDermTech$15.66M0.00N/AN/A$1.67 per share0.00MGRXMangoceuticals$620K12.88N/AN/A$4.30 per share0.36SSYSunLink Health Systems$31.09M0.20N/AN/A$2.00 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)DMTKDermTech-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/AMGRXMangoceuticals-$8.71M-$4.64N/A∞N/A-2,191.76%-72.81%-66.58%8/13/2025 (Estimated)SSYSunLink Health Systems-$1.53M$0.246.33∞N/A3.20%-20.94%-16.09%N/ALatest DMTK, BRTX, MGRX, and SSY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MGRXMangoceuticalsN/A-$1.29N/A-$1.29N/A$0.11 million5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXBiorestorative TherapiesN/AN/AN/AN/AN/ADMTKDermTechN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/ASSYSunLink Health SystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXBiorestorative TherapiesN/A2.242.24DMTKDermTechN/A3.533.46MGRXMangoceuticalsN/A0.120.12SSYSunLink Health SystemsN/A4.063.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXBiorestorative Therapies69.38%DMTKDermTech20.45%MGRXMangoceuticals56.72%SSYSunLink Health Systems23.67%Insider OwnershipCompanyInsider OwnershipBRTXBiorestorative Therapies25.50%DMTKDermTech5.10%MGRXMangoceuticals16.00%SSYSunLink Health Systems27.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXBiorestorative Therapies77.50 million5.59 millionNot OptionableDMTKDermTech26034.96 million33.18 millionOptionableMGRXMangoceuticals35.17 million4.34 millionNot OptionableSSYSunLink Health Systems1,3767.04 million5.08 millionNot OptionableDMTK, BRTX, MGRX, and SSY HeadlinesRecent News About These CompaniesSunlink Health Systems Extends Merger Agreement DeadlineJune 23, 2025 | tipranks.comSunLink Health Systems, Inc. Announces Fiscal 2025 Third Quarter ResultsMay 13, 2025 | businesswire.comREGIONAL HEALTH PROPERTIES AND SUNLINK HEALTH SYSTEMS REVISE ALL-STOCK MERGER TRANSACTIONApril 15, 2025 | markets.businessinsider.comSunLink Health Systems, Inc. Announces Fiscal 2025 Second Quarter ResultsFebruary 12, 2025 | businesswire.comRegional Health Properties to merge with Sunlink Health SystemsJanuary 8, 2025 | mcknightsseniorliving.comMRegional Health, SunLink Health to merge in all-stock transactionJanuary 7, 2025 | markets.businessinsider.comSunLink Health Systems Inc (SSY) Stock Trading RecapJanuary 7, 2025 | bovnews.comBRegional Health Properties Shares More Than Double on SunLink Health DealJanuary 6, 2025 | marketwatch.comShareholder Alert: Ademi LLP Investigates Whether SunLink Health Systems, Inc. Is Obtaining a Fair Price for Its Public ShareholdersJanuary 6, 2025 | stockhouse.comSSY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of SunLink Health Systems, Inc. Is Fair to ShareholdersJanuary 6, 2025 | tmcnet.comSunLink Health Systems Inc (SSY) Stock: Beyond the Surface of Its Performance?December 27, 2024 | bovnews.comBSunLink Health Systems IncNovember 18, 2024 | uk.investing.comSunLink Health Systems, Inc. Announces Fiscal 2025 First Quarter ResultsNovember 13, 2024 | accesswdun.comAJPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into FridayOctober 12, 2024 | msn.comSunLink Health Systems, Inc. Announces Sale of Trace Regional Hospital Real EstateOctober 10, 2024 | finance.yahoo.comSunLink Health Systems (AMEX:SSY) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSunLink Health Systems, Inc. Announces Fiscal 2024 Fourth Quarter and Annual ResultsSeptember 30, 2024 | businesswire.comSunLink Health Systems, Inc. (SSY)August 1, 2024 | finance.yahoo.comSunLink Health Systems, Inc. Announces Sale of Trace Extended Care & RehabJune 3, 2024 | businesswire.comSSY Stock Earnings: SunLink Health Systems Reported Results for Q3 2024May 15, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMTK, BRTX, MGRX, and SSY Company DescriptionsBiorestorative Therapies NASDAQ:BRTX$1.58 -0.01 (-0.38%) As of 07/3/2025 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.DermTech NASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Mangoceuticals NASDAQ:MGRX$1.54 +0.03 (+1.64%) Closing price 07/3/2025 03:28 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.SunLink Health Systems NYSE:SSY$0.89 -0.02 (-2.11%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$0.88 0.00 (-0.11%) As of 07/3/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SunLink Health Systems, Inc., through its subsidiaries, provides healthcare products and services in the southeastern United States. It operates in two segments, Healthcare Services and Pharmacy. The Healthcare Services segment owns and operates a 49-licensed-bed acute care hospital, which includes a 26-bed geriatric psychiatry unit; two clinics; and a 66-bed extended care and rehabilitation centre. This segment also provides information technology services; and owns five acers unimproved lands. The Pharmacy segment offers institutional pharmacy services consisting of provision of specialty and non-specialty pharmaceutical and biological products, such as nursing homes, assisted living facilities, behavioural and specialty hospitals, hospices, and correctional facilities; non-institutional pharmacy services, including private residences; and durable medical equipment products and services, including the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care, as well as retails pharmacy products and services. SunLink Health Systems, Inc. was incorporated in 1959 and is based in Atlanta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
